+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

MagForce AG (MF6) - Product Pipeline Analysis, 2020 Update

  • PDF Icon

    Company Profile

  • 37 Pages
  • November 2020
  • GlobalData
  • ID: 4400027
Summary

MagForce AG (MagForce) is a medical device manufacturing company. The company is engaged in the development of nanotechnology-based therapy for the treatment of cancer. It's products portfolio include NanoActivator, NanoTherm, NanoPlan and NanoTherm Therapy. The NanoActivator creates a magnetic field that can be used to treat tumors in all areas of the body. The company's NanoTherm is a liquid containing nanoparticles that reacts to the presence of magnetic field. It's NanoPlan uses the bioheat transfer equation to help the physician in charge estimate treatment temperatures and the magnetic field strength. MagForce is headquartered in Berlin, Germany.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company MagForce AG
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

MagForce AG Company Overview
  • MagForce AG Company Snapshot
  • MagForce AG Pipeline Products and Ongoing Clinical Trials Overview
  • MagForce AG - Pipeline Analysis Overview
  • MagForce AG - Key Facts
  • MagForce AG - Major Products and Services
  • MagForce AG Pipeline Products by Development Stage
  • MagForce AG Ongoing Clinical Trials by Trial Status

MagForce AG Pipeline Products Overview
  • NanoTherm - Brain Cancer
  • NanoTherm - Brain Cancer Product Overview
  • NanoTherm - Gastrointestinal Cancer
  • NanoTherm - Gastrointestinal Cancer Product Overview
  • NanoTherm - Pancreatic Carcinoma
  • NanoTherm - Pancreatic Carcinoma Product Overview
  • NanoTherm - Prostate Carcinoma
  • NanoTherm - Prostate Carcinoma Product Overview
  • NanoTherm - Prostate Carcinoma Clinical Trial
  • NanoTherm - Recurrent Glioblastoma
  • NanoTherm - Recurrent Glioblastoma Product Overview
  • Next-Generation Nanotherm
  • Next-Generation Nanotherm Product Overview

MagForce AG - Key Competitors
  • MagForce AG - Key Employees
  • MagForce AG - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Recent Developments
  • MagForce AG, Recent Developments
  • Oct 31, 2019: MagForce publishes financial results for the first half of 2019 and operative highlights
  • Jun 20, 2019: MagForce publishes financial results for the year 2018 and operative highlights
  • Apr 04, 2019: MagForce: Inauguration ceremony marks official opening of new NanoTherm Treatment Center at Independent Public Clinical Hospital No. 4 in Lublin, Poland
  • Mar 21, 2019: MagForce successfully completes installation of mobile NanoTherm treatment center for brain tumors in Poland
  • Feb 06, 2019: MagForce: Newly launched ’NanoTherm Therapy School’ kicks off with successful first training session
  • Oct 23, 2018: MagForce publishes financial results for the first half of 2018 and operative highlights
  • Jul 02, 2018: MagForce Announces Enrollment of First Patient in its Pivotal, Three-Stage, Single-Arm Study of Focal Ablation of Prostate Cancer with NanoTherm Therapy
  • Jun 14, 2018: MagForce Co-Sponsors the University Hospital of Munster’s Annual Brain Cancer Patient Event
  • Jun 12, 2018: MagForce Announces Collaboration Agreement for NanoTherm Therapy with Independent Public Clinical Hospital No. 4, Lublin, Poland
  • Jun 04, 2018: MagForce to host Lunch Symposium about Local Therapies for Malignant Gliomas at the 2018 meeting of the German Society of Neurosurgery (DGNC)

Appendix
  • Methodology
  • About the Publisher
  • Contact
  • Disclaimer

List of Tables
  • MagForce AG Pipeline Products and Ongoing Clinical Trials Overview
  • MagForce AG Pipeline Products by Equipment Type
  • MagForce AG Pipeline Products by Indication
  • MagForce AG Ongoing Clinical Trials by Trial Status
  • MagForce AG, Key Facts
  • MagForce AG, Major Products and Services
  • MagForce AG Number of Pipeline Products by Development Stage
  • MagForce AG Pipeline Products Summary by Development Stage
  • MagForce AG Ongoing Clinical Trials by Trial Status
  • MagForce AG Ongoing Clinical Trials Summary
  • NanoTherm - Brain Cancer - Product Status
  • NanoTherm - Brain Cancer - Product Description
  • NanoTherm - Gastrointestinal Cancer - Product Status
  • NanoTherm - Gastrointestinal Cancer - Product Description
  • NanoTherm - Pancreatic Carcinoma - Product Status
  • NanoTherm - Pancreatic Carcinoma - Product Description
  • NanoTherm - Prostate Carcinoma - Product Status
  • NanoTherm - Prostate Carcinoma - Product Description
  • NanoTherm - Prostate Carcinoma - An Investigational Device Exemption, Phase III Study of NanoTherm therapy as Focal Ablation Treatment for Intermediate Risk Prostate Cancer
  • NanoTherm - Prostate Carcinoma - Next Stage of Pivotal U.S. Study Evaluate the Safety of NanoTherm therapy system for the Focal Ablation of Intermediate Risk Prostate Cancer
  • NanoTherm - Recurrent Glioblastoma - Product Status
  • NanoTherm - Recurrent Glioblastoma - Product Description
  • Next-Generation Nanotherm - Product Status
  • Next-Generation Nanotherm - Product Description
  • MagForce AG, Key Employees
  • MagForce AG, Other Locations
  • MagForce AG, Subsidiaries
  • Glossary

List of Figures
  • MagForce AG Company Overview

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pulsion Medical Systems SE
  • Nanobiotix SA
  • German Cancer Research Center
  • Dragerwerk AG & Co KGaA
  • Curetis NV